



Preliminary scientific program

Orally Inhaled Products - Guideline Update

Carolien Versantvoort (CBG-MEB)

Requirements from Draft Nasal and Inhaled Products Example of Dissolution for Inhaled Products

Jean-Michel Cardot (SAS BORVO)

OIP - Where We Are and Where We Go

Vít Perlík (Pharmacology, Faculty of Medicine, CU, CADORE)

ICH M15 Model-Informed Drug Development General Principles Guideline

Pavel Farkaš (TEVA / PLIVA)

Navigating the Science: Exploring the Development and Validation of Dosing Guidance Tools

Martin Wolfsegger (TAKEDA)

NTIDs - Alpha Inflation

Paulo Paixão (University of Lisbon)

Biosimilar New Guideline for In Vivo Waivers

René Anour (AGES)

OTC Status for Products - National Specificities

Paolo Biffignandi (VI.REL Pharma)

M13A Final and Associated Q&A, Comments

Susana Almeida (International Generic and Biosimilar Medicines Association)

African Medicines Agency

Loice Kikwai (LCK Pharmaceutical Consulting)